Ovation Pharmaceuticals, Inc. And Cardinal Health, Inc. Announce FDA Approval Letter For Manufacturing Of Biologic Therapy To Treat Rare Genetic Disorder

DEERFIELD, Ill. and DUBLIN, Ohio, Sept. 6 /PRNewswire-FirstCall/ -- OVATION Pharmaceuticals, Inc. and Cardinal Health, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued an approval letter for Cardinal Health’s new sterile facility in North Raleigh, N.C. to manufacture Panhematin® (hemin for injection), an Ovation biologic therapy used to treat acute porphyria, a rare genetic disorder.